-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
A statistical guide to Scott Gottlieb, President Donald Trump’s pick to head the FDA
Scott Gottlieb, 44, has deep ties to the pharma industry as an investor and consultant but he has also worn many hats in a career that included two previous stints at the FDA, practicing as a physician, and writer/editor roles at prestigious medical journals.
-
Ex-FDA boss Califf optimistic about 21st Century Cures, skeptical of Trump
Dr. Robert Califf, who stepped down last month, offers five tips about keeping Americans safe — and making sure drugs actually work — after about a year overseeing the federal agency.
-
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
-
At least 6 senators grilling HHS nominee Tom Price also hold healthcare stocks
At least six members of the two Senate committees tasked with questioning or confirming Tom Price for HHS secretary hold shares in healthcare companies — such as Merck, Medtronic and Gilead — according to a Kaiser Health News analysis.
-
Pharma companies routinely bend orphan drug rules
A Kaiser Health News investigation shows that the system intended to help desperate patients is being manipulated by drugmakers to maximize profits and to protect niche markets for medicines already being taken by millions.
-
Tech, providers win, while safety, prevention lose in 21st Century Cures Act
The bill is a grab bag for industries that spent plenty of money lobbying to make sure it happened that way.
-
21st Century Cures Act, brought to you by an army of lobbyists
Other than major appropriations bills, a transportation spending bill and an energy infrastructure funding bill, the 21st Century Cures Act garnered more lobbying activity than any of the more than 11,000 bills proposed in the 114th Congress.
-
Lucrative pharma jobs leave FDA with hundreds of vacancies
The FDA has more than 700 job vacancies in its division that reviews new drugs, and the agency has been under fire for taking too long to approve medications.
-
Hospitals push back against massive inpatient drug price inflation
Inpatient drug spending increased by 23.4 percent annually from 2013 to 2015, according to a new report commissioned by the American Hospital Association and the Federation of American Hospitals.